2015•The Brown University Psychopharmacology UpdateRequires access
SSRIs in combination with clopidogrel
Y. W. Francis Lam
Open publisher page 0 citations
Abstract
Clopidogrel is an antiplatelet drug commonly used to inhibit platelet aggregation after acute coronary events and interventions. It is a prodrug that requires CYP2C19-mediated metabolism to its active metabolite. Patients with genetic deficiency or low enzyme activity of CYP2C19 would experience reduced effectiveness of clopidogrel, and in these patients alternative antiplatelet therapy should be considered.1